PATRIARCA F.

Last name: PATRIARCA F.

2017 (v1)

Publication

Metadata-only

Erratum to: Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation [Biol Blood Marrow Transplant (2017) 23 (333–339)] (S1083879116304839) (10.1016/j.bbmt.2016.11.005)

Patriarca F. Cigana C. Dozzo M.

In the above-mentioned article, the third author's name was printed incorrectly. The correct author name should read Massimo Dozzo.

Uploaded on: March 27, 2023
2017 (v1)

Publication

Metadata-only

Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation

Patriarca F. Cigana C. Massimo D.

The objective of this study was to determine risk factors and outcomes of infections by multidrug-resistant gram-negative (MDR GN) bacteria in 241 recipients of hematopoietic stem cell transplantation (HSCT). The cumulative incidence of infections was 10.5% (95% CI, 12.0% to 25.8%), with 57% of infections occurring during the period of severe...

Uploaded on: April 14, 2023
2019 (v1)

Publication

Metadata-only

The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma

Tolomelli G. Mancuso K. Tacchetti P.

Plerixafor inhibits CXCR4, thus inducing the mobilization of hematopoietic stem/progenitor cells in lymphoma and multiple myeloma (MM) patients eligible for autologous stem cell transplantation (ASCT). However, the kinetics of plerixafor-induced mobilization of lymphocyte subsets is poorly known. Here, we evaluated the graft content, the...

Uploaded on: April 14, 2023
2021 (v1)

Publication

Metadata-only

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial

Mina R. Falcone A. P. Bringhen S.

No description

Uploaded on: March 27, 2023
2021 (v1)

Publication

Metadata-only

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial

Gay F. Musto P. Rota-Scalabrini D.

Background: Bortezomib-based induction followed by high-dose melphalan (200 mg/m2) and autologous stem-cell transplantation (MEL200-ASCT) and maintenance treatment with lenalidomide alone is the current standard of care for young and fit patients with newly diagnosed multiple myeloma. We aimed to evaluate the efficacy and safety of different...

Uploaded on: April 14, 2023

PATRIARCA F.

Recent uploads